Development Alliance

Angle PLC
11 August 2004

For Immediate Release                                             11 August 2004

                                    ANGLE plc

                     NERVE INJURY AND PAIN DRUG DISCOVERY

                ALLIANCE BY VENTURE COMPANY NEUROTARGETS LTD


ANGLE plc ('ANGLE') is pleased to announce that NeuroTargets Ltd, a
discovery-led biotechnology company specialising in diseases of nerve injury and
pain founded by ANGLE in 1999, has formed a development alliance with BioFocus
plc, a world leader in collaborative drug discovery.

Under the terms of this agreement, NeuroTargets and BioFocus will apply their
complementary expertise to discover lead compounds and drug candidates that bind
to a specific receptor involved in nerve repair.  It is anticipated that
candidates with proven safety and efficacy will be licensed to pharmaceutical
companies for late stage clinical development and commercialisation.

This new partnership combines NeuroTargets' leading expertise in target
validation and product screening with BioFocus's proven capability in early
stage drug discovery, resulting in a significant step forward in NeuroTargets'
strategic move from a genomics-based company into one that develops novel
therapeutic products for disorders related to nerve injury.

Dr David Kennard, recently appointed Chief Executive of NeuroTargets said:

'We are extremely pleased to be working with BioFocus because of their proven
ability to identify quality candidates from validated targets.  This alliance
represents a significant development for NeuroTargets from research into a
product based company developing drugs for nerve injury disorders. '

Geoff McMillan, BioFocus's Chief Executive, said:

'We are delighted to establish a relationship with NeuroTargets, a specialist
provider of drug development expertise. This collaboration highlights BioFocus's
intent to identify and exploit its core capabilities in GPCR drug discovery by
augmenting our established pipeline and increasing downstream value through
strategic partnership.'

For further information

ANGLE plc                               01483 295830
Andrew Newland, Chief Executive
Dawson Buck, Deputy Chief Executive

Buchanan Communications                 020 7466 5000
Richard Darby, Suzanne Brocks


Notes to Editors

Founded in 1994, ANGLE is an international venture management and consulting
company focusing on the commercialisation of technology and the development of
technology-based industry. ANGLE creates, develops and advises technology
businesses on its own behalf and for its clients.


About NeuroTargets

NeuroTargets discovers and develops new drugs for neurological diseases. The
Company has developed a highly efficient, patented technology for discovering
novel and rarely expressed genes, which are associated with neuropathy, such as
diabetic neuropathy, and neuropathic pain. It has validated a number of
promising drug targets, including the second galanin receptor sub-type, and a
chemokine receptor.

NeuroTargets was founded in 1999 by ANGLE plc to commercialise the research of
Professor David Wynick of Bristol University.  The company's strategy involves
the identification and development of product candidates to the end of phase II
clinical studies, funded through a combination of collaborations and
shareholders' funds. (www.neurotargets.co.uk).


                      This information is provided by RNS
            The company news service from the London Stock Exchange